Research over the past decade has revealed multiple potential mechanisms by which dendritic cells contribute to the immunopathogenesis of systemic lupus erythematosus. Genetic abnormalities in ...

Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active L ...

Future Rheumatol. 2008;3(3):269-279. These phenotypic abnormalities, at least in part, appear to be intrinsic to the mDCs, as the addition of lupus serum to healthy control or lupus mDCs could not ...

WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus standard of care (SoC) ...

Cohort analyses from the WILLOW study reveal clear proof of concept in patients with CLE and SLE with active lupus rash, showing clinically meaningful ...

Accropeutics reports positive data from phase 2 trial of AC-201, an oral, selective TYK2/JAK1 inhibitor, to treat moderate-to-severe plaque psoriasis: New York Thursday, May 22, 2 ...

Some patients with lupus who possess specific antibodies are at a higher risk of thrombotic events such as a blood clot, stroke or heart attack, a new study led by Johns Hopkins ...

Here we investigated the impact of HFD on lupus pathogenesis and autoimmunity using lupus-prone mice. Methods Thirty male and 30 female MRL/lymphoproliferation (lpr) mice were fed with regular diet ...

Antibodies targeting the TFAM protein could increase the risk of blood clotting complications in people with lupus, a study ...

Autoimmune diseases develop when the immune system mistakenly attacks the body’s own tissues by recognizing self-antigens as ...